Abstract 533P
Background
Docetaxel (DTX) + ramucirumab (RAM) is one of the standard treatment options in second-line setting after first-line platinum-based chemotherapy plus ICI. The SCORPION study, phase II trial evaluating the efficacy and safety of DTX plus RAM after first-line platinum-based chemotherapy plus ICI, demonstrated encouraging antitumor activity with a manageable safety profile. However, the clinical benefit of RAM in elderly patients is not fully elucidated. Here, we report the subset analysis of the elderly patients in SCORPION study.
Methods
The primary end point of the study was objective response rate (ORR), and secondary endpoints were disease control rate (DCR), progression-free survival (PFS), and safety etc. Patients were treated with 60 mg/m2 of DTX and 10 mg/kg of RAM on day 1 with strong recommendation of pegfilgrastim on day 2 every 3 weeks.
Results
Thirty-three patients were recruited from 8 institutions. Median age (range) was 66 (42–79) y, 15 patients (45%) were aged ≤ 65, while 6 (18%) were aged ≥ 75. As previously reported, the primary endpoint was met as 11 of 32 patients achieved PR with ORR at 34.4% (80%CI, 23.1-47.2), and median PFS was 6.5 months. In elderly patients with aged ≥ 75 years, the ORR and disease control rate were 16.7 % and 100%, respectively (1 in 6 pts had a PR and all 6 pts had their disease controlled). Median PFS was 8.5 months. No treatment-related deaths and no new safety signals were observed in elderly patients aged ≥ 75 years.
Conclusions
DTX plus RAM showed favorable DCR with 8.5 months of PFS in elderly patients aged ≥ 75 years. Although our analysis was based on small subset, DTX plus RAM could be a treatment option even in elderly patients who failed first-line platinum-based chemotherapy plus ICI.
Clinical trial identification
jRCTs041190077.
Editorial acknowledgement
Legal entity responsible for the study
Masahiro Morise.
Funding
Eli Lilly Japan K.K.
Disclosure
T. Yamaguchi: Financial Interests, Personal, Speaker’s Bureau: Ono Pharmaceutical, Chugai Pharmaceutical, Eli Lilly, Taiho Pharmaceutical, AstraZeneca, MSD, Bristol-Myers Squibbb. R. Matsuzawa: Financial Interests, Personal, Speaker’s Bureau: Boehringer Ingelheim, AstraZeneca, Pfizer, Eli Lilly, Chugai Pharmaceutical, MSD, Ono Pharmaceutical, Taiho Pharmaceutical. M. Morise: Financial Interests, Institutional, Research Grant: Boehringer Ingelheim, Eli Lilly; Financial Interests, Personal, Speaker’s Bureau: Eli Lilly, Chugai, AstraZeneca, Ono, Pfizer, MSD; Non-Financial Interests, Personal, Non financial benefits: F. Hoffmann-La Roche; Financial Interests, Institutional, Local PI: Chugai, AstraZeneca, Ono, Pfizer, Merk Serono, Kissei, Taiho, Novartis. K. Ito: Financial Interests, Personal, Speaker’s Bureau: Boehringer Ingelheim, AstraZeneca, Pfizer, Eli Lilly, Chugai Pharmaceutical, MSD, Ono Pharmaceutical, Taiho Pharmaceutical, Takeda, Daiichi Sankyo. O. Hataji: Financial Interests, Institutional, Research Grant: AstraZeneca, Novartis, MSD, Daiichi Sankyo, Bayer Yakuhin, AbbVie, Eli Lilly, Janssen, Ono; Financial Interests, Personal, Speaker’s Bureau: AstraZeneca, Chugai, Takeda, MSD, Merck, Daiichi Sankyo, Eli Lilly, AbbVie, Boehringer Ingelheim, Nippon Kayaku, Taiho. K. Takahashi: Financial Interests, Personal, Speaker’s Bureau: AstraZeneca, Boehringer Ingelheim, Chugai, Eli Lilly, GSK, MSD, Nippon Kayaku, Novartis, Pfizer, Taiho, Takeda. Y. Goto: Financial Interests, Personal, Invited Speaker: Taiho Pharmaceutical CO., LTD, Nippon Boehringer Ingelheim CO., LTD., Chugai Pharmaceutical CO., LTD., Chugai Pharmaceutical CO., LTD., MSD K.K., AstraZeneca K.K., GSK K.K., Pfizer Japan Inc., Takeda Pharmaceutical CO., LTD., Nippon Kayaku Co., Ltd., Novartis Japan, Bristol Myers Squibb K.K., KYOWA HAKKO BIO CO., Ltd., Eli Lilly Japan K.K. H. Itani: Financial Interests, Personal, Speaker’s Bureau: Eli Lilly. Y. Zenke: Financial Interests, Personal, Invited Speaker: AstraZeneca, Lilly, Chugai, Boehringer Ingelheim, Ono pharmaceutical, Bristol Myers Squibb, Takeda pharmaceutical, Taiho pharmaceutical, MSD, Novartis, Nippon Kayaku, Amgen, Kyowa-Hakko Kirin; Financial Interests, Personal, Advisory Board: Daiichi Sankyo; Financial Interests, Institutional, Research Grant: AstraZeneca, MSD, Merck, Daiichi Sankyo, Amgen. M. Oki: Financial Interests, Institutional, Research Grant: AbbVie, Chugai, GSK, MSD, Parexel, Sanofi, AstraZeneca, Fujifilm Toyama Chemical, Janssen, Ono and Pfizer; Financial Interests, Personal, Speaker’s Bureau: AMCO, Canon Medical Systems, Fujifilm Toyama Chemical, Merit Medical Japan, Olympus, AstraZeneca, Chugai, Kaneka Medix, Novartis, and Sanofi. M. Ishii: Financial Interests, Personal, Speaker’s Bureau: AstraZeneca, GSK, Pfizer, Shionogi, Sanofi, Insmed, Asahi Kasei Pharma, Kyorin pharmaceutical, Chugai pharmaceutical, Boehringer Ingelheim, Eli Lilly, Daiichi Sankyo, MSD, Abbott, Taiho pharmaceutical, Amgen, Novartis. All other authors have declared no conflicts of interest.
Resources from the same session
122P - Distinct transcriptomic immune profiling and clinicopathological features of cribriform morphology in colorectal adenocarcinomas
Presenter: Abdelhakim Khellaf
Session: Poster Display
Resources:
Abstract
123P - Spatial molecular profiling identifies FGF20 upregulation on cancer-associated fibroblast and FGFR2-PI3K/Akt activation in tumor cells of sporadic early-onset colon cancer
Presenter: Dave Hoon
Session: Poster Display
Resources:
Abstract
124P - Characteristics, prognosis and therapeutic effects of non-V600 BRAF mutated colorectal cancer
Presenter: Lalida Arsa
Session: Poster Display
Resources:
Abstract
125P - Final results of APOLLON-11 and SOYUZ-APOLLON study: Multicentre prospective observational post-authorization study of bevacizumab biosimilar in patients with metastatic colorectal cancer in real-world practice
Presenter: Alexey Tryakin
Session: Poster Display
Resources:
Abstract
126P - From tumor height (TH) to tumor regression grade (TRG) in locally advanced rectal cancers (LARC) during total neadjuvant therapy (TNT): A retrospective analysis
Presenter: Valeria Pusceddu
Session: Poster Display
Resources:
Abstract
127P - A meta-analysis of efficacy and safety from head-to-head first-line (1L) trials of epidermal growth factor receptor inhibitors (EGFRIs) versus bevacizumab in combination with chemotherapy (CT) doublets in patients with RAS wild-type (WT) metastatic colorectal cancer (mCRC) by sidedness
Presenter: Takayuki Yoshino
Session: Poster Display
Resources:
Abstract
128TiP - A phase II study of cadonilimab + FOLFOXIRI and bevacizumab as initial therapy for unresectable proficient mismatch repair/microsatellite stable (pMMR/MSS) metastatic colorectal cancer (mCRC)
Presenter: Rongbo Lin
Session: Poster Display
Resources:
Abstract
140P - Prevalence of claudin-18 isoform 2 (CLDN18.2) positivity in locally advanced (LA) unresectable or metastatic gastric or gastroesophageal junction (mg/GEJ) adenocarcinoma in patients (pts) in the Asia region: Phase III SPOTLIGHT and GLOW studies
Presenter: Hoo Hwoei Fen Soo
Session: Poster Display
Resources:
Abstract
141P - Early phase trials outcomes in refractory upper GI cancers: A 10-year analysis from the SCRI UK phase I unit
Presenter: Antonella Cammarota
Session: Poster Display
Resources:
Abstract
142P - The survival impact of the addition of durvalumab to cisplatin/gemcitabine in advanced biliary tract cancer: A real-world, retrospective, multicentric study
Presenter: Silvia Foti
Session: Poster Display
Resources:
Abstract